Enliven Therapeutics (ELVN) Stock Forecast & Price Target

$24.51 +0.16 (+0.66%)

(As of 01:13 PM ET)

Enliven Therapeutics - Analysts' Recommendations and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Buy

Based on 4 Analyst Ratings

Sell
0

Hold
0

Buy
4

Based on 4 Wall Street analysts who have issued ratings for Enliven Therapeutics in the last 12 months, the stock has a consensus rating of "Buy." Out of the 4 analysts, 3 have given a buy rating, and 1 has given a strong buy rating for ELVN.

Consensus Price Target

$37.00
50.96% Upside

According to the 4 analysts' twelve-month price targets for Enliven Therapeutics, the average price target is $37.00. The highest price target for ELVN is $40.00, while the lowest price target for ELVN is $34.00. The average price target represents a forecasted upside of 50.96% from the current price of $24.51.

Get the Latest News and Ratings for ELVN and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Enliven Therapeutics and its competitors.

ELVN Analyst Ratings Over Time

Type	Current Forecast 11/28/23 to 11/27/24	1 Month Ago 10/29/23 to 10/28/24	3 Months Ago 8/30/23 to 8/29/24	1 Year Ago 11/28/22 to 11/28/23
Strong Buy	1 Strong Buy rating(s)	1 Strong Buy rating(s)	1 Strong Buy rating(s)	0 Strong Buy rating(s)
Buy	3 Buy rating(s)	3 Buy rating(s)	2 Buy rating(s)	3 Buy rating(s)
Hold	0 Hold rating(s)	0 Hold rating(s)	0 Hold rating(s)	0 Hold rating(s)
Sell	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)
Consensus Price Target	$37.00	$34.33	$33.00	$27.00
Forecasted Upside	50.96% Upside	19.80% Upside	48.51% Upside	133.56% Upside
Consensus Rating	Buy	Buy	Buy	Buy

I've got news for you… (Ad)

Today, I’m doing something I thought I’d never do… Especially since I’m not normally a “swing for the fences” type of trader. But I’ve been quietly testing a new type of trade for a while now… And the returns are too good not to share with you. Take a look… I can’t guarantee results or against losses, but if you want to discover how I’ll target the triple return before the end of the week

watch this FREE briefing with me and expert trader Graham Lindman

ELVN Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

ELVN Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

Enliven Therapeutics Stock vs. The Competition

Type	Enliven Therapeutics	Medical Companies	S&P 500
Consensus Rating Score	3.25	2.80	2.50
Consensus Rating	Buy	Moderate Buy	Moderate Buy
Predicted Upside	51.95% Upside	25,238.47% Upside	6.73% Upside
News Sentiment Rating	Neutral News See Recent ELVN News	Positive News	Positive News

Recent Analyst Forecasts and Stock Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export to Excel

Date	Brokerage	Analyst Name	Action	Rating	Price Target	Upside/Downside on Report Date
11/15/2024	Robert W. Baird 2 of 5 stars		Boost Target	Outperform ➝ Outperform	$32.00 ➝ $40.00	+60.51%
10/1/2024	HC Wainwright 2 of 5 stars	R. Burns Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$37.00 ➝ $37.00	+39.05%
6/11/2024	Baird R W 0 of 5 stars	C. Kusy Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
4/9/2024	Mizuho Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Buy	$34.00	+85.79%
3/29/2023	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Buy	$27.00	+14.94%
3/7/2023	Lifesci Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	S. Slutsky Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform
3/3/2023	TD Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Outperform

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Wednesday at 01:50 PM ET.

ELVN Forecast - Frequently Asked Questions

: According to the research reports of 4 Wall Street equities research analysts, the average twelve-month stock price forecast for Enliven Therapeutics is $37.00, with a high forecast of $40.00 and a low forecast of $34.00.
: 4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Enliven Therapeutics in the last twelve months. There are currently 3 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" ELVN shares.
: According to analysts, Enliven Therapeutics's stock has a predicted upside of 50.96% based on their 12-month stock forecasts.
: Enliven Therapeutics has been rated by research analysts at HC Wainwright, and Robert W. Baird in the past 90 days.
: Analysts like Enliven Therapeutics more than other "medical" companies. The consensus rating for Enliven Therapeutics is Buy while the average consensus rating for "medical" companies is Moderate Buy. Learn more on how ELVN compares to other companies.

Stock Forecasts and Research Tools

Related Companies

Today's Ratings

Top Rated Stocks

More Ratings Tools

Unveiled: NVIDIA’s "Secret Royalty" Program (Ad)

Did you know that there's an investment that will give you the opportunity to collect "royalties" every time Nvidia makes a chip?

Click Here to learn how to get in now >>>

This page (NASDAQ:ELVN) was last updated on 11/27/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Enliven Therapeutics (ELVN) Stock Forecast & Price Target